URIMAR-T- methenamine, sodium phosphate, monobasic, monohydrate, phenyl salicylate, methylene blue, and hyoscyamine sulfate tabl

Nazione: Stati Uniti

Lingua: inglese

Fonte: NLM (National Library of Medicine)

Principio attivo:

METHENAMINE (UNII: J50OIX95QV) (METHENAMINE - UNII:J50OIX95QV), SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN) (PHOSPHATE ION - UNII:NK08V8K8HR, SODIUM CATION - UNII:LYR4M0NH37), PHENYL SALICYLATE (UNII: 28A37T47QO) (PHENYL SALICYLATE - UNII:28A37T47QO), METHYLENE BLUE (UNII: T42P99266K) (METHYLENE BLUE CATION - UNII:ZMZ79891ZH), HYOSCYAMINE SULFATE (UNII: F2R8V82B84) (HYOSCYAMINE - UNII:PX44XO846X)

Commercializzato da:

Marnel Pharmaceuticals, LLC

INN (Nome Internazionale):

Methenamine

Composizione:

Methenamine 120 mg

Via di somministrazione:

ORAL

Tipo di ricetta:

PRESCRIPTION DRUG

Indicazioni terapeutiche:

URIMAR-T™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. Urimar-T™ is contraindicated in patients with a hypersensitivity to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). A dependence on the use of URIMAR-T™ has not been reported and due to the nature of its ingredients, abuse of URIMAR T™ is not expected.

Dettagli prodotto:

Urimar-T™ are blue to blue-violet speckled, capsule-shaped tablets imprinted with 334 on one side and plain on the other, available in bottles of 100 tablets, (NDC: 0682-0334-01), and sample tablets of 1, (NDC: 0682-0334-10). Store in a cool, dry place at controlled room temperature 15° to 30°C (59° to 86°F). Keep container tightly closed. Protect from moisture and direct sunlight. Dispense in a tight, light-resistant container as defined in the USP/NF with a child resistant closure. WARNING: Keep this and all drugs out of reach of children.

Stato dell'autorizzazione:

unapproved drug other

Scheda tecnica

URIMAR-T- METHENAMINE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE,
PHENYL SALICYLATE,
METHYLENE BLUE, AND HYOSCYAMINE SULFATE TABLET
MARNEL PHARMACEUTICALS, LLC
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
URIMAR-T™
RX ONLY
DESCRIPTION
URIMAR-T™ for oral administration.
EACH TABLET CONTAINS:
Methenamine
120 mg
Sodium Phosphate Monobasic
40.8 mg
Phenyl Salicylate
36.2 mg
Methylene Blue
10.8 mg
Hyoscyamine Sulfate
0.12 mg
INACTIVE INGREDIENTS: colloidal silicon dioxide, lactose, polyethylene
glycol, crospovidone,
magnesium stearate, FD&C Lake Blue #1.
METHENAMINE
[100-97-0] 1,3,5,7-Tetraazatricyclo [3.3.1.-1
] decane; hexamethylenetetramine; HMT; HMTA;
hexamine; 1,3,5,7-tetraazaadamantane hexamethylenemine; Uritone;
Urotropin. C
H
N
; mol wt
140.19; C 51.40%, H 8.63%, N 39.96%. Methenamine
(hexamethylenetetramine) exists as colorless,
lustrous crystals or white crystalline powder. Its solutions are
alkaline to litmus. Freely soluble in
water, soluble in alcohol and in chloroform.
SODIUM PHOSPHATE MONOBASIC
[7558-80-7] Phosphoric acid sodium salt (1:1); Sodium biphosphate;
sodium dihydrogen phosphate;
acid sodium phosphate; monosodium orthophosphate; primary sodium
phosphate; H
NaO
P; mol wt
119.98, H 1.68%, Na 19.16%, O 53.34%, P 25.82%. Monohydrate, white,
odorless slightly deliquesce
crystals or granules. At 100° C loses all its water; when ignited it
converts to metaphosphate. It is
freely soluble in water and practically insoluble in alcohol. The
aqueous solution is acid. pH of 0.1
molar aqueous solution at 25° C: 4.5.
PHENYL SALICYLATE
[118-55-8] 2-Hydroxybenzoic acid phenyl ester; Salol. C
H
O
; mol wt 214.22, C 72.89%, H
4.71%, O 22.41%. Made by the action of phosphorus oxy-chloride on a
mixture of phenol and salicylic
acid. Phenyl Salicylate exists as white crystals with a melting point
of 41°-43° C. It is very slightly
soluble in water and freely solu